for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

日医工株式会社

4541.T

現在値

389.00JPY

変化

54.00(+16.12%)

出来高

9,123,800

本日のレンジ

337.00

 - 

400.00

52週レンジ

196.00

 - 

979.00

∙ 約20分前の相場を表示しています。

適時開示

EMA Reviews Dexamethasone For Treating Adults With COVID-19 Requiring Respiratory Support

July 24 (Reuters) - EMA::EMA - REVIEWING RESULTS FROM RECOVERY STUDY ARM THAT INVOLVED THE USE OF DEXAMETHASONE IN THE TREATMENT OF PATIENTS WITH COVID-19 ADMITTED TO HOSPITAL.EMA - RECOVERY STUDY RECORDED DEATHS DURING 28 DAYS AFTER STARTING DEXAMETHASONE TREATMENT.EMA - PRELIMINARY RESULTS INDICATE DEXAMETHASONE REDUCED MORTALITY BY ABOUT 35% IN PATIENTS ON INVASIVE MECHANICAL VENTILATION VERSUS WITH USUAL CARE.EMA - PRELIMINARY RESULTS INDICATE DEXAMETHASONE REDUCED MORTALITY BY ABOUT 20% IN PATIENTS RECEIVING OXYGEN WITHOUT INVASIVE VENTILATION.EMA - PRELIMINARY RESULTS INDICATE DEXAMETHASONE DID NOT REDUCE DEATH IN PATIENTS WHO WERE NOT RECEIVING OXYGEN THERAPY.

Sagent Pharmaceuticals Announces FDA Acceptance Of Omega Manufacturing Site

Sept 5 (Reuters) - Sagent Pharmaceuticals::SAGENT PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF OMEGA MANUFACTURING SITE.SAGENT PHARMACEUTICALS - OMEGA LABORATORIES LTD HAS BEEN FOUND ACCEPTABLE FOR MANUFACTURING FDA-APPROVED PRODUCTS.

Nichi-Iko Pharmaceutical announces exercise of options

Nov 12(Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:Says 20,000 units of its ninth series options were exercised to 2 million shares of its common stock on Nov. 12.

Nichi-Iko Pharmaceutical announces exercise of options

Aug 29(Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:Says 16,500 units of its ninth series options were exercised to 1.65 million shares of its common stock on Aug. 15 and Aug. 29.

Lupin Partners With Nichi-Iko For Commercialization Of Biosimilar Etanercept In Japan

June 18 (Reuters) - Lupin Ltd <LUPN.NS>::SAYS CO, NICHI-IKO ANNOUNCE PARTNERSHIP FOR COMMERCIALIZATION OF BIOSIMILAR ETANERCEPT IN JAPAN.SAYS PRODUCT WILL BE LAUNCHED BY NICHI-IKO AFTER RECEIVING APPROVAL FROM PHARMACEUTICALS AND MEDICAL DEVICES AGENCY.

Nichi-Iko Pharmaceutical says application of International Financial Reporting Standards

April 9 (Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:Says it will apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japanese Generally Accepted Accounting Principles.IFRS effective from the annual report for fiscal year ended March 2018.

Nichi-Iko Pharmaceutical says business and capital alliance with Eisai

March 28 (Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:Says it forms business and capital alliance with Eisai Co Ltd <<<4523.T>>>.Says two entities will mainly cooperate on generic drug business model reform, ecosystem construction and API application .Says it will acquire 100 percent stake in ELMED EISAI Co Ltd from Eisai Co Ltd, for 17.12 billion yen in total.Says it plans to complete stake acquisition on April 1, 2019 .

Nichi-Iko Pharmaceutical to start sales of Infliximab BS for I.V. Infusion 100mg "Nichi-Iko"

Nov 28 (Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:Says it will start sales of Infliximab BS for I.V. Infusion 100mg "Nichi-Iko" on Nov. 29.

Nichi-Iko Pharmaceutical says merger with wholly owned unit

Oct 2(Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:Says it merged with a wholly owned unit, on Oct. 1.

Nichi-Iko Pharmaceutical and unit says marketing approval for Infliximab BS for I.V. Infusion 100 mg "Nichi-Iko" and "AYUMI"

Sept 27 (Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:* Says it received marketing approval for Infliximab BS for I.V. Infusion 100 mg "Nichi-Iko" from the Ministry of Labour, Health, and Welfare on Sept. 27 .* Says its unit, Yakuhan Pharmaceutical Co Ltd, received manufacturing and marketing approval for Infliximab BS for I.V. infusion 100 mg "AYUMI" .

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up